The effectiveness of cannabis to address the underlying causes and complications of pre-diabetes and diabetes is, of course, still being researched but is very promising.
Every medical professional seems to have their pet ailments, and diabetes is one of mine. In 2012, the total healthcare cost for diagnosed cases of diabetes in the United States was 245 billion dollars. By the year 2020, that healthcare hit will soar to at least half a trillion dollars.
Diabetes is a group of metabolic conditions in which the body does not produce enough insulin or has become resistant to its effects. Insulin is a hormone required to convert sugar, starches, and other food into energy. The two most common forms of diabetes are designated type 1 and type 2. In type 1 diabetes, the pancreas does not produce insulin. Type 2 is a much more common form, typically affecting adults, and is associated with obesity. In type 2 diabetes, the body becomes resistant to insulin, which enables glucose to accumulate to dangerous levels within the body. High glucose levels damage vascular and other tissues, resulting in heart disease, stroke, blindness, and kidney and nerve damage. According to a National Institute of Health Review, diabetes is the leading cause of preventable blindness among adults.
Molecules to target diabetes
The endocannabinoid system plays a vital role in the development of diabetes and its complications. Diabetic complications linked to the endocannabinoid system include blindness, kidney failure, heart disease, and neuropathic pain. Cannabinoids with reduced or no psychoactivity, including CBD, CBDV, and THCV, are of much interest in maintaining pancreatic function and reducing insulin resistance. Recent research indicates that CBD plays a significant role in preventing retinal damage associated with diabetes by acting as an antioxidant and enhancing the retina’s defenses against inflammation.
THCv is also of great interest because of its ability to suppress appetite and regulate blood sugar levels and reduce insulin resistance. I believe that the THCV molecule will be a significant contributor to the prevention and treatment of diabetes. High THCV cannabis is difficult to find in the United States. High CBD strains are increasingly easy to find. CBDV cannabis is not readily available and may actually exist in the United States but as yet unidentified simply because of lack of lab testing for this particular cannabinoid. As far as the terpenes go, you can hardly ever go wrong with myrcene, limonene, and pinene.
Dosing for diabetes
The suggested dose for the treatment of pre-diabetes and diabetes is dependent on the dominant cannabinoid (THC, CBD, THCV, CBDV, etc.). More research will clarify the appropriate dose and combination of Phytocannabinoids for addressing these conditions.
Methods of ingestion
Vaporized cannabis has been shown to ease the neuropathic pain of diabetic subjects. In an article published recently in The Journal of Pain, researchers at the University of California, San Diego, evaluated the effectiveness of vaporized cannabis in comparison with a placebo in 16 subjects with allogenic diabetic peripheral neuropathic pain (DPN).
Authors noted: “This small, short-term, placebo-controlled trial of inhaled cannabis demonstrated a dose-dependent reduction in diabetic peripheral neuropathy pain in patients with treatment-refractory pain. Overall, our finding of an analgesic effect of cannabis is consistent with other trials of cannabis in diverse neuropathic pain syndromes.”
Both oral and vaporized uses of high CBD/CBDV and THCV strains will likely be proven to be beneficial in controlling metabolic illnesses such as diabetes. Of course, you need a little THC due to the depressive properties of THCV.
Pummeled to Death by Hamburger: The Tale of a Man’S Lifetime on the Fringes of the Medical Cannabis Industry